Pivanex

SKU: orb1307868

Description

Pivanex (Pivalyloxymethyl butyrate) is an orally bioavailable histone deacetylase (HDAC) inhibitor with demonstrated antimetastatic and antiangiogenic properties. Research indicates it downregulates Bcr-Abl protein levels and induces apoptosis, showing activity in both in vitro cancer cell studies and in vivo animal models of leukemia and solid tumors.

Research Area

Cardiovascular Research, Cell Biology, Epigenetics & Chromatin, Molecular Biology, Signal Transduction

Key Properties

• CAS Number: 122110-53-6
• MW: 202.25
• Purity: ≥98%
• Formula: C₁₀H₁₈O₄
• SMILES: CCCC(=O)OCOC(=O)C(C)(C)C
• Target: Apoptosis,HDAC,Bcr-Abl
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (19.78 mM);DMSO:100 mg/mL (494.44 mM)

Bioactivity

• In Vivo:
  Pivanex treatment also marked delays in the end stage of disease as defined by the onset of body mass loss. Pivanex (200 mg/kg, b.i.d, daily) obviously improves the survival of SMN7 SMA mice .
• In Vitro:
  Pivanex has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Pivanex (200 μM) causes enhancement in the G2-M phase, moderate enhancement in the S phase, and a slight reduction in G0-G1 of the cell cycle. Pivanex (100-500 μM) shows significant anti-proliferation activity in K562 cells. Pivanex (100-500 μM) also increases apoptosis and caspase activity in K562 cells .

Storage & Handling

• Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

K562, myelogenous, muscular, inhibit, lung, NSCLC, lymphoblastic, leukemia, Inhibitor, HDAC, Histone deacetylases, ALL, Acute, Bcr-Abl, BcrAbl, cancer, Apoptosis, AN 9, AN9, AN-9, atrophy, CML, Chronic, spinal, Pivanex, Pivalyloxymethyl butyrate, Pivalyloxymethyl Butyrate

Compound Identifiers

PubChem CID

60748